Grip

Grip Bio is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory, fibrotic, and autoimmune diseases by modulating Natural Killer T (NKT) cells. The company's lead candidate, GRI-0621, is a small molecule inhibitor of Type 1 invariant NKT cells, currently being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF). By targeting NKT cells, which act as "master controllers" of the immune response, Grip Bio aims to intervene early in the inflammatory cascade to prevent tissue damage and fibrosis. The company's pipeline also includes NKT cell activators for autoimmune conditions like Systemic Lupus Erythematosus and modulators for chronic liver diseases. Grip Bio is headquartered in La Jolla, California, and is committed to addressing significant unmet medical needs through its proprietary NKT cell platform.